Fiduciary Trust’s Rhythm Pharmaceuticals RYTM Stock Holding History

Fiduciary Trust’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$1.01M	–	885
2025 Q3	$1.01M	Hold	10,000	–	–	0.01%	412
2025 Q2	$632K	Sell	10,000 -5,000	-33%	-$306K	0.01%	489
2025 Q1	$795K	Sell	15,000 -5,000	-25%	-$277K	0.01%	436
2024 Q4	$1.12M	Hold	20,000	–	–	0.01%	336
2024 Q3	$1.05M	Hold	20,000	–	–	0.01%	353
2024 Q2	$821K	Hold	20,000	–	–	0.01%	369
2024 Q1	$867K	Hold	20,000	–	–	0.01%	371
2023 Q4	$919K	Hold	20,000	–	–	0.02%	351
2023 Q3	$459K	Hold	20,000	–	–	0.01%	453
2023 Q2	$330K	Hold	20,000	–	–	0.01%	526
2023 Q1	$357K	Hold	20,000	–	–	0.01%	504
2022 Q4	$582K	Sell	20,000 -10,000	-33%	-$257K	0.01%	430
2022 Q3	$735K	Buy	30,000 +10,000	+50%	+$186K	0.02%	369
2022 Q2	$83K	Buy	+20,000	New	+$109K	﹤0.01%	615

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fiduciary Trust's RYTM Position: Q4 2025 in Review

Fiduciary Trust sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 10,000 shares — an estimated $1.01M sold.

Fiduciary Trust first reported a position in RYTM in Q2 2022 and held it in 14 quarters. The position peaked at $1.12M in Q4 2024. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

Fiduciary Trust reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Fiduciary Trust sold 10,000 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $1.01M.
Fiduciary Trust first reported a position in Rhythm Pharmaceuticals in Q2 2022 and held it in 14 quarters.
Fiduciary Trust's Rhythm Pharmaceuticals position peaked at $1.12M in Q4 2024.
279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Fiduciary Trust's 13F filing for Q4 2025, filed 13 Feb 2026.